A Pre-Cellular Therapy Observational Study in Early Huntington's Disease (PRE-CELL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01937923|
Recruitment Status : Completed
First Posted : September 10, 2013
Last Update Posted : November 1, 2016
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
This observational study will establish a clinical baseline and measure changes over time in movement, thinking, behavior, brain imaging, blood and spinal fluid markers in subjects with early stage Huntington's disease. Participants enrolled in this study may be eligible to participate in a future planned study of stem cell therapy for Huntington's Disease (HD).
In-person study visits occur at screening, baseline, and every 6 months thereafter for a minimum of 12 months, with interim phone call assessments.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||29 participants|
|Official Title:||A Pre-Cellular Therapy Observational Study in Early Huntington's Disease|
|Study Start Date :||August 2013|
|Actual Primary Completion Date :||July 2016|
|Actual Study Completion Date :||July 2016|
- Rate of change from baseline in white matter volume on magnetic resonance imaging (MRI) brain scan. [ Time Frame: Baseline and 12 or 18 months ]
- Rate of change from baseline on the UHDRS total motor score [ Time Frame: Baseline and 12 or 18 months ]
- Rate of change from baseline on the Total Functional Capacity score [ Time Frame: Baseline and 12 or 18 months ]
Biospecimen Retention: Samples Without DNA
Safety labs: Complete blood count, comprehensive metabolic panel, international normalized ration, partial thromboplastic time, thyroid stimulating hormone, urinalysis, HIV screen.
Biomarkers: Brain-derived neurotrophic factor (BDNF) in cerebrospinal fluid (CSF) and Plasma, BDNF related and Huntington's Disease (HD) specific gene transcription markers in CSF and blood, Small molecule markers of HD in CSF and plasma
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
- Men or women age 18 and older, English speaking, able to give informed consent and comply with study procedures.
- HD diagnosis confirmed with genetic testing demonstrating CAG trinucleotide repeat length (CAGn) greater than 37
- Early stage HD with Total Functional Capacity (TFC) score of 9-13
- Demonstrable motor signs with a Unified Huntington's Disease Rating Scale (UHDRS) diagnostic confidence level of 4
- Must have a caregiver or informant able to give feedback about the participant and willing to report observations about subject on standardized forms.
- Subjects of child bearing potential must agree to adequate birth control measures including intrauterine device, hormone therapy, hormone rings or barrier methods including foams/gels AND condoms.
- Very early disease without demonstrable motor signs (diagnostic confidence level < 4)
- Significant cognitive impairment or dementia as defined by Montreal Cognitive Assessment (MoCA) score < 12.
- Moderate or advanced disease with TFC < 9
- Concurrent active unstable psychiatric disease including history of suicide attempts within the last year, major personality or psychiatric disorders.
- History of concurrent serious medical illness such as HIV or current anti-retroviral treatment, cancer, major cardiac, pulmonary, immunological or other organ disease.
- History of coagulopathy, bleeding disorder, or concurrent use of blood thinners.
- History of brain tumor, serious traumatic brain injury with coma, or history of brain surgery.
- Any comorbid condition that presents an unacceptable health risk to the patient in the investigator's view
- Clinically significant laboratory test abnormalities, including full blood count, chemistry panel, liver function tests, Prothrombin time/international normalized ratio (PT/INR), lipid panel, electrocardiogram (EKG), or chest x-ray as judged by the investigator.
- Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with safety or adherence to study requirements.
- History or documentation of contraindication for MRI brain scan, including the presence of pacemaker, neurostimulator, aneurysm clips, artificial heart valves, cochlear implants, metal fragments in the eyes, orbits or skin or any other known contraindication to MRI.
- Any significant MRI brain scan findings other than those characteristic of HD.
- Any contraindications to surgery or to the use of general anesthesia, including allergy.
- History of use of any investigational agent within 60 days prior to enrollment
- History of current or previous gene therapy or stem cell therapy.
- History of previous or current treatment with cytokines
- History of sensitivity to ganciclovir.
- Pregnant and/or lactating women
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01937923
|United States, California|
|UC Davis Medical Center, Clinical Research Center|
|Sacramento, California, United States, 95817|
|Principal Investigator:||Vicki Wheelock, MD||University of California, Davis|
|Responsible Party:||University of California, Davis|
|Other Study ID Numbers:||
DR2A-05415 ( Other Grant/Funding Number: CIRM )
|First Posted:||September 10, 2013 Key Record Dates|
|Last Update Posted:||November 1, 2016|
|Last Verified:||October 2016|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
Basal Ganglia Diseases
Central Nervous System Diseases
Nervous System Diseases
Heredodegenerative Disorders, Nervous System
Genetic Diseases, Inborn